Last Updated : May 10, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Lorbrena | lorlatinib | ALK-positive locally advanced or metastatic non-small cell lung | Reimburse with clinical criteria and/or conditions | Complete | ||
| Padcev | enfortumab vedotin | Locally advanced or metastatic urothelial carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Imvexxy | estradiol | Dyspareunia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Pemazyre | pemigatinib | Cholangiocarcinoma | Do not reimburse | Complete | ||
| HyQvia | immune globulin human and recombinant human hyaluronidase | Humoral immunodeficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
| Bijuva | estradiol and progesterone | Vasomotor symptoms associated with menopause | Reimburse with clinical criteria and/or conditions | Complete | ||
| Trodelvy | sacituzumab govitecan | Locally advanced or metastatic triple-negative breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | nivolumab | Esophageal or gastroesophageal junction cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Sarclisa | isatuximab | Multiple myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Darzalex | daratumumab | Light chain (AL) amyloidosis | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 10, 2024